Help Pharmacy Safety, Regulation & Compliance Posture

What Makes Help a 503B Outsourcing Facility?

Help Pharmacy operates under Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), a classification Congress created through the Drug Quality and Security Act of 2013 following the deadly fungal meningitis outbreak linked to the New England Compounding Center (NECC) [1]. That outbreak killed 76 people and sickened over 750 patients who received contaminated methylprednisolone injections [2]. The distinction matters. Traditional 503A pharmacies compound medications based on individual prescriptions and face primarily state-level oversight. A 503B outsourcing facility, by contrast, may produce compounded drugs without patient-specific prescriptions and distributes them to healthcare facilities, but it accepts direct FDA oversight in return.

Under this framework, Help must register with the FDA, report adverse events, comply with current Good Manufacturing Practices (cGMP), and submit to regular FDA inspections [1]. The FDA maintains a public list of all registered outsourcing facilities, and Help has appeared on that registry continuously since its 503B registration. As of early 2026, the FDA lists approximately 76 active registered outsourcing facilities nationwide [3]. Help ranks among the largest by prescription volume and revenue.

The 503B pathway does not mean FDA approval of individual compounded products. No compounded drug receives FDA approval through this route. What the registration does provide is a higher regulatory floor than traditional compounding pharmacies, with federal inspection authority, adverse event reporting requirements, and manufacturing standards that more closely mirror those of conventional pharmaceutical manufacturers.

FDA Inspection History and Form 483 Observations

Help's FDA inspection record shows a pattern common among large 503B facilities: repeated inspections, some resulting in Form 483 observations, followed by documented corrective actions. The FDA conducts inspections of outsourcing facilities on a risk-based schedule, and public records from these inspections are available through the FDA's inspection database [3].

Form 483 observations are not recalls or enforcement actions. They are documented findings an investigator believes may constitute violations of the FD&C Act. A 2020 GAO report found that 65% of all outsourcing facility inspections between 2014 and 2019 resulted in at least one Form 483 observation [4]. Receiving observations is common; the response and correction timeline matters more than the observation itself.

Help has received Form 483 observations related to environmental monitoring, cleaning validation, and documentation practices across multiple inspection cycles. The company has publicly stated that it addressed each observation with corrective and preventive actions (CAPAs). The FDA has not issued a warning letter to Help as of this review, which places it in a more favorable position than several competitors who have received warning letters or injunctions.

For comparison, the FDA has issued warning letters to multiple 503B facilities since 2020, and two outsourcing facilities have faced federal injunctions for persistent cGMP violations [3]. The absence of warning letters or consent decrees in Help's record is a meaningful differentiator, though it does not guarantee future compliance.

Accreditation and Quality Standards

Help holds accreditation from the Pharmacy Compounding Accreditation Board (PCAB), a voluntary accreditation program administered by the Accreditation Commission for Health Care (ACHC). PCAB accreditation requires on-site surveys evaluating quality management systems, personnel training, facility design, and compounding procedures [5].

The pharmacy also reports compliance with United States Pharmacopeia (USP) chapters that govern compounding standards. USP General Chapter 795 covers nonsterile compounding, USP 797 addresses sterile compounding, and USP 800 establishes standards for handling hazardous drugs [6]. Revised USP 797 standards, which took effect in November 2023 after years of delay, imposed stricter beyond-use dating requirements and more rigorous environmental monitoring for sterile compounding [6]. Help has stated it meets these updated requirements.

These accreditations are voluntary. Many 503B outsourcing facilities operate without PCAB accreditation and rely solely on meeting minimum FDA and state requirements. The decision to pursue PCAB accreditation signals investment in quality infrastructure, though accreditation alone does not prevent quality failures.

Dr. Allen Loyd, a pharmacist and former editor of the International Journal of Pharmaceutical Compounding, has noted: "Accreditation bodies like PCAB provide an additional layer of scrutiny, but they supplement rather than replace FDA oversight. The real test is whether a facility's quality systems function consistently under production pressure" [5].

Compounded GLP-1 Agonists: Regulatory Context

Help became widely known in the telehealth and weight-management space through its compounded semaglutide products, which it produced while semaglutide appeared on the FDA Drug Shortage List. The FDA permits 503B outsourcing facilities to compound copies of commercially available drugs only when those drugs are on the official shortage list [7].

In October 2024, the FDA removed semaglutide from the shortage list after Novo Nordisk reported adequate supply of Wegovy and Ozempic [7]. This decision triggered legal and regulatory challenges. The Outsourcing Facilities Association filed suit against the FDA, and several 503B pharmacies, including Help, sought clarity on transition timelines for existing patients.

The FDA issued guidance indicating that outsourcing facilities should wind down production of compounded semaglutide within a defined period following the shortage resolution [7]. Some facilities continued producing semaglutide salts (such as semaglutide sodium) that they argued were not copies of the commercially available product. The FDA subsequently stated that certain salt forms of semaglutide may still qualify for compounding under specific conditions, though enforcement positions have continued to evolve through 2025 and into 2026 [8].

For patients considering compounded GLP-1 products from Help or any compounding pharmacy, the clinical evidence base for compounded versions is thinner than for FDA-approved products. The STEP-1 trial (N=1,961) demonstrated 14.9% mean body weight loss at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo [9]. That trial used the FDA-approved formulation manufactured by Novo Nordisk, not a compounded version. Compounded semaglutide has not been tested in comparable randomized controlled trials, and bioequivalence data are not publicly available for most compounded formulations.

How Help Compares to Other 503B Facilities

The 503B outsourcing facility market includes approximately 76 registered operations as of 2026, but fewer than 20 account for the majority of prescription volume [3]. Comparing Help to its peers requires examining several dimensions.

Regulatory standing. Help has not received an FDA warning letter. By contrast, facilities such as Fagron Sterile Services received a warning letter in 2023 for cGMP violations, and NuVision Pharmacy faced an FDA injunction [3]. This places Help in the upper tier of regulatory compliance among high-volume 503B operations.

Testing protocols. Help reports batch-level sterility testing, bacterial endotoxin testing (BET), and potency verification on injectable products. These practices align with FDA expectations for 503B facilities and USP 797 requirements [6]. Some smaller 503B facilities perform only periodic rather than batch-level testing.

Scale and capacity. Help's Houston facility exceeds 100,000 square feet and employs over 800 staff, making it one of the largest compounding operations in the country. Scale can be a double-edged consideration: larger operations have resources for better quality systems, but production volume also increases the statistical probability of batch deviations.

Transparency. Help publishes certificates of analysis (CoAs) and has made its quality management approach part of its public messaging. Not all 503B facilities provide equivalent transparency to prescribers or patients.

The Pew Charitable Trusts has tracked compounding pharmacy safety data since 2012 and recommended that all 503B facilities undergo annual FDA inspections, a standard that the agency has not consistently met due to resource constraints [10]. A 2023 Pew analysis found that the FDA inspected only 57% of registered outsourcing facilities within the prior 18 months [10].

State Licensure and Legal Compliance

Help holds pharmacy licenses in all 50 states, the District of Columbia, and several U.S. territories. State boards of pharmacy impose their own requirements on compounding pharmacies operating within their jurisdictions, and these requirements vary substantially.

Some states, such as California and Massachusetts, have enacted compounding regulations that exceed federal minimums. The Massachusetts Board of Registration in Pharmacy, for example, implemented enhanced inspection protocols after the NECC disaster, given that the NECC was based in Framingham, Massachusetts [2]. Maintaining licensure across all 50 states requires ongoing compliance with a patchwork of state-specific rules covering everything from labeling to beyond-use dating to controlled substance handling.

State disciplinary actions are tracked by individual state boards and the National Association of Boards of Pharmacy (NABP). Patients and prescribers can verify Help's license status through their state board's online lookup tools or through NABP's verification system [11].

Adverse Event Reporting and Pharmacovigilance

As a 503B facility, Help is required to report serious adverse events to the FDA through the MedWatch system within 15 calendar days [3]. This is the same reporting obligation that applies to conventional drug manufacturers. Traditional 503A compounding pharmacies do not have this federal reporting requirement.

The FDA Adverse Event Reporting System (FAERS) database is publicly searchable, and reports associated with outsourcing facilities can be retrieved through FAERS queries [12]. Adverse event reports in FAERS do not establish causation. They indicate that a patient experienced a negative outcome while using a product, but confounding factors, underlying conditions, and reporting biases limit the conclusions that can be drawn from individual reports.

Dr. Scott Gottlieb, former FDA Commissioner, stated during his tenure: "The 503B framework was designed specifically to bring compounding pharmacies that operate at scale under a level of federal oversight proportional to the risk they pose to public health" [1]. That framework depends on consistent FDA inspection resources and facility cooperation with reporting obligations.

Cost Considerations

Help's compounded products typically cost less than their FDA-approved equivalents. Compounded semaglutide, when available, was priced between $150 and $400 per month depending on dose and formulation, compared to Wegovy's list price of approximately $1,349 per month before insurance [13]. Compounded testosterone cypionate for TRT generally costs $30 to $80 per month through Help, versus $75 to $250 or more for brand-name formulations at retail pharmacies.

These price differences reflect several factors. Compounded drugs do not carry the R&D amortization of FDA-approved products. They also lack the marketing, distribution, and regulatory submission costs that branded manufacturers absorb. The trade-off is that compounded products have not undergone the same clinical trial program, and patients assume a different risk profile.

Insurance coverage for compounded products is inconsistent. Most commercial insurers do not cover compounded medications, meaning patients pay out-of-pocket. Some telehealth platforms that partner with Help bundle the pharmacy cost into a subscription model, which can obscure the per-unit medication price.

What Does Help Pharmacy Prescribe?

Help does not prescribe. It is a pharmacy, not a medical practice. Prescriptions are written by licensed healthcare providers (physicians, nurse practitioners, or physician assistants) who then send orders to Help for compounding and dispensing. This distinction is important because the prescribing decision, including indication, dosing, and monitoring, rests with the clinician, not the pharmacy.

Help's formulary includes compounded formulations across several therapeutic categories: injectable and sublingual testosterone, estradiol, progesterone, thyroid hormones, peptides (including BPC-157 and PT-141), and, when permitted by shortage status, GLP-1 receptor agonists. The pharmacy also compounds oral and topical medications.

Patients should confirm that their prescribing provider conducts appropriate baseline labs (complete metabolic panel, CBC, lipid panel, hormone levels, and HbA1c where relevant) and establishes a monitoring schedule before initiating compounded hormone therapy or GLP-1 treatment. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends monitoring hematocrit, PSA, and lipids at baseline, 3 to 6 months, and then annually [14].